A bold new way to test cancer drugs started Monday. Like a medical version of speed dating, doctors will sort through multiple experimental drugs and match patients to the one most likely to succeed based on each person's unique tumor gene profile. Five drug companies, the government, private foundations and advocacy groups are taking part.
Researchers have determined that a copper compound known for decades may form the basis for a therapy for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. In a new study, scientists showed in laboratory animal tests that oral intake of this compound significantly extended the lifespan and improved the locomotor function of transgenic mice that are genetically engineered to develop this debilitating and terminal disease.
An international team of scientists, led by researchers at the Univ. of California, San Diego School of Medicine, have identified the genes encoding a molecule that famously defines Group A Streptococcus (strep), a pathogenic bacterial species responsible for more than 700 million infections worldwide each year.
One of the defining features of cells is their membranes. Each cell’s repository of DNA and protein-making machinery must be kept stable and secure from invaders and toxins. Scientists have attempted to replicate these properties, but, despite decades of research, even the most basic membrane structures, known as vesicles, still face many problems when made in the laboratory.
Staph infections that become resistant to multiple antibiotics don't happen because the bacteria themselves adapt to the drugs, but because of a kind of genetic parasite they carry called a plasmid that helps its host survive the antibiotics. Plasmids are rings of bare DNA containing a handful of genes that are essentially freeloaders, borrowing most of what they need to live from their bacterial host.
Merck will spend nearly $4 billion for Idenix Pharmaceuticals with a per-share bid that more than triples the hepatitis C drug developer's latest closing price. Pharmaceutical companies are racing to test new and potentially lucrative treatments for hepatitis C, a blood-borne disease that causes liver damage and is expected to become more common as the U.S. population ages.
In the battle against stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), a new single-dose antibiotic is as effective as a twice-daily infusion given for up to 10 days, according to a large study led by Duke Medicine researchers. Researchers said the advantage of the new drug, oritavancin, is its potential to curtail what has been a key driver of antibiotic resistance.
The first preclinical study of a new Rice Univ.-developed anticancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells without harming surrounding normal organs. The research reports that Rice’s “quadrapeutics” technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors.
Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anticancer drugs and are capable of introducing a “cocktail” of multiple drugs into cancer cells. The researchers are all part the joint biomedical engineering program at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill.
A pathway to the design of even more effective versions of the powerful anticancer drug Taxol has been opened with the most detailed look ever at the assembly and disassembly of microtubules, tiny fibers of tubulin protein that form the cytoskeletons of living cells and play a crucial role in mitosis.
Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration for clinical trials in cancer patients. The new report, published in Angewandte Chemie, focuses on a compound called TIC10.
Photodynamic therapy (PDT) is an effective treatment for easily accessible tumors such as oral and skin cancer. But the procedure, which uses lasers to activate special drugs called photosensitizing agents, isn’t adept at fighting cancer deep inside the body. That could change because of a new technology that could bring PDT into areas of the body which were previously inaccessible.
Researchers have created a prototype system that uses a mathematical model to predict—and a portable inkjet technology to produce—precise medication dosages tailored for specific patients, an advance in personalized medicine that could improve drug effectiveness and reduce adverse reactions.
A comparatively new form of a medication for alcohol and opioid dependence that’s injected once a month instead of taken orally once a day appears to be significantly more effective than some other medications—because more patients actually continue the prescribed regimen. The findings offer support for a wider use of medications that may help reduce or prevent substance abuse and related hospital admissions.
In pharmaceutical production, identifying enzyme catalysts that help improve the speed and efficiency of the process can be a major boon. Figuring out exactly why a particular enzyme works so well is an altogether different quest. Take the cholesterol-lowering drug simvastatin.
The human body is full of proteins called enzymes that help nearly every function in the body. Scientists have been studying enzymes for decades in order to learn how they work and how to create better drugs and medical treatments for many ailments. Now, Univ. of Missouri researchers have completed a 3-D map of an enzyme called Proline utilization A (PutA).
Chemists in the College of Arts and Sciences at Syracuse Univ. have figured out how to control multiple bacterial behaviors—potentially good news for the treatment of infectious diseases and other bacteria-associated issues, without causing drug resistance.
Agilent Technologies Inc. has announced the signing of a memorandum of understanding with Seoul National Univ., Korea's top research university, on a new research center that will support the College of Pharmacy's New Drug Development Center. The collaboration will conduct drug metabolism studies, develop new compounds, study remedial effects and toxicity, assess pharmacokinetics, and conduct clinical tests for drugs.
Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. The method can be likened to keeping a cancer-killing bomb and its detonator separate until they are inside a cancer cell, where they then combine to destroy the cell.
Massachusetts Institute of Technology researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage. In studies with mice, the research team showed that this one-two punch, which relies on a nanoparticle that carries two drugs and releases them at different times, dramatically shrinks lung and breast tumors.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital. Four patients are still alive after more than two-and-a-half years and without additional treatment.
Patients who use medical marijuana for pain and other chronic symptoms can take an unwanted hit: Insurers don't cover the treatment, which costs as much as $1,000 a month. Once the drug of choice for hippies and rebellious teens, marijuana in recent years has gained more mainstream acceptance for its ability to boost appetite, dull pain and reduce seizures in everyone from epilepsy to cancer patients.
For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications. Virologists at the Univ. of Missouri now are testing the next generation of medications that stop HIV from spreading, and are using a molecule related to flavor enhancers found in soy sauce.
Rice Univ. scientists have designed a tunable virus that works like a safe deposit box. It takes two keys to open it and release its therapeutic cargo. The Rice team developed an adeno-associated virus (AAV) that unlocks only in the presence of two selected proteases, enzymes that cut up other proteins for disposal. Because certain proteases are elevated at tumor sites, the viruses can be designed to target and destroy the cancer cells.
Northwestern Medicine scientists have newly identified a protein’s key role in cell and physiological aging and have developed—in collaboration with Tohoku Univ. in Japan—an experimental drug that inhibits the protein’s effect and prolonged the lifespan in a mouse model of accelerated aging. The rapidly aging mice fed the experimental drug lived more than four times longer than a control group.